FR2358153A1 - Composition pharmaceutique a base d'organophosphonate et de sulfoxyde - Google Patents

Composition pharmaceutique a base d'organophosphonate et de sulfoxyde

Info

Publication number
FR2358153A1
FR2358153A1 FR7721558A FR7721558A FR2358153A1 FR 2358153 A1 FR2358153 A1 FR 2358153A1 FR 7721558 A FR7721558 A FR 7721558A FR 7721558 A FR7721558 A FR 7721558A FR 2358153 A1 FR2358153 A1 FR 2358153A1
Authority
FR
France
Prior art keywords
organophosphonate
sulfoxide
pharmaceutical composition
composition based
organosulfoxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7721558A
Other languages
English (en)
Other versions
FR2358153B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of FR2358153A1 publication Critical patent/FR2358153A1/fr
Application granted granted Critical
Publication of FR2358153B1 publication Critical patent/FR2358153B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composition utilisable pour le traitement topique d'une mobilisation anormale et d'un dépôt de phosphates de calcium dans les tissus d'êtres humains et d'animaux supérieurs. Cette composition contient : 1. Une quantité inoffensive et efficace d'un organophosphonate; et 2. Un véhicule qui comprend une quantité inoffensive et efficace d'un organosulfoxyde. L'organosulfoxyde facilite la pénétration à travers la peau de l'agent actif organophosphonate.
FR7721558A 1976-07-15 1977-07-12 Composition pharmaceutique a base d'organophosphonate et de sulfoxyde Granted FR2358153A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70565076A 1976-07-15 1976-07-15

Publications (2)

Publication Number Publication Date
FR2358153A1 true FR2358153A1 (fr) 1978-02-10
FR2358153B1 FR2358153B1 (fr) 1979-05-11

Family

ID=24834378

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7721558A Granted FR2358153A1 (fr) 1976-07-15 1977-07-12 Composition pharmaceutique a base d'organophosphonate et de sulfoxyde

Country Status (9)

Country Link
JP (1) JPS5334930A (fr)
AU (1) AU2649977A (fr)
BE (1) BE856849A (fr)
CA (1) CA1100874A (fr)
DE (1) DE2731366A1 (fr)
FR (1) FR2358153A1 (fr)
GB (1) GB1582694A (fr)
NL (1) NL7707849A (fr)
NZ (1) NZ184496A (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407344A2 (fr) * 1989-07-07 1991-01-09 Ciba-Geigy Ag Préparations pharmaceutiques pour application topique
US5139786A (en) * 1989-07-07 1992-08-18 Ciba-Geigy Corporation Topical formulations

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59117882A (ja) * 1982-12-25 1984-07-07 Kazuo Hashimoto ドア−スコ−プ
JPS59148479A (ja) * 1983-02-14 1984-08-25 Aihon Kk 集合住宅用テレビ・インタ−ホンシステム
JPS6139788A (ja) * 1984-07-31 1986-02-25 Toshiba Electric Equip Corp 集合住宅インタ−ホンシステム
JPH0822059B2 (ja) * 1985-02-07 1996-03-04 アイホン株式会社 テレビ通話装置
JPS63234792A (ja) * 1987-03-24 1988-09-30 Izumi Soken Eng:Kk 無人受付案内システム
US7820197B2 (en) 2002-02-14 2010-10-26 Astellas Pharma Inc. Percutaneous preparations
JPWO2008032678A1 (ja) 2006-09-11 2010-01-28 救急薬品工業株式会社 貼付剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2328234A1 (de) * 1972-06-08 1974-01-03 Procter & Gamble Mittel zur inhibierung der mobilisierung von calciumphosphat

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2328234A1 (de) * 1972-06-08 1974-01-03 Procter & Gamble Mittel zur inhibierung der mobilisierung von calciumphosphat

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407344A2 (fr) * 1989-07-07 1991-01-09 Ciba-Geigy Ag Préparations pharmaceutiques pour application topique
EP0407344A3 (en) * 1989-07-07 1991-06-12 Ciba-Geigy Ag Pharmaceutical preparation for topical application
US5133972A (en) * 1989-07-07 1992-07-28 Ciba-Geigy Corporation Topically administrable pharmaceutical preparations
US5139786A (en) * 1989-07-07 1992-08-18 Ciba-Geigy Corporation Topical formulations

Also Published As

Publication number Publication date
BE856849A (fr) 1978-01-16
FR2358153B1 (fr) 1979-05-11
DE2731366A1 (de) 1978-01-19
NL7707849A (nl) 1978-01-17
GB1582694A (en) 1981-01-14
CA1100874A (fr) 1981-05-12
AU2649977A (en) 1979-01-04
JPS5334930A (en) 1978-03-31
NZ184496A (en) 1980-08-26

Similar Documents

Publication Publication Date Title
FR2445146A1 (fr) Medicament a prise orale contenant une substance inhibitrice de l'inflammation et un ou plusieurs phospholipides
DE69034148D1 (de) Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie
DE3850026D1 (de) Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren.
CA2273017A1 (fr) Dispositif d'administration locale de formulations solides ou semi-solides, formulations retard pour administration parenterale et procede de preparation
FR2393573A1 (fr) Preparations capillaires contenant un copolymere de vinylpyrrolidone
DE69110561D1 (de) Mittel zur Behandlung und Vorbeugung von Bauchentzündungen, die als Wirkstoff Zink-L-Carnosin-Salze oder -Komplexe enthalten.
DE3789576D1 (de) Verwendung von Inositol-Triphosphat zur Behandlung von Metallvergiftung.
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
FR2358153A1 (fr) Composition pharmaceutique a base d'organophosphonate et de sulfoxyde
ATE79761T1 (de) Behandlung einer krankheit vom aids-typ.
NL960024I2 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus besmette patiënten.
DK211989D0 (da) Molekylfaelde og anvendelse deraf
FR2387033A1 (fr) Composition therapeutique contenant une ou plusieurs substances actives chimiquement modifiees
ATE58900T1 (de) Diaryldiazolylmethane.
ATE158950T1 (de) Behandlung der autoimmunen uveoretinitis in menschen
FR2420974A1 (fr) Medicament a base de derives de l'uracile
Hunskaar A case of ecthyma contagiosum (human orf) treated with idoxuridine
DE3784628D1 (de) Dermale behandlung von wurmerkrankungen der katze mit praziquantel.
DE3582935D1 (de) Mittel zur behandlung von erkrankungen der venen und des analbereichs.
FR2572286B1 (fr) Utilisation du 1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide pour le traitement de maladies virales chez l'homme
ATE348885T1 (de) Peptide zur behandlung des systemischen lupus erythematosus
TNSN95068A1 (fr) Oligonucleotides pour inhiber le role des isoprenyl proteine transferases
FR2392032A1 (fr) 8-n-glucuronide de 8-amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoleine, son procede de preparation et son application en therapeutique
Babu et al. Recovery of benthiocarb-inhibited AChE in fish brain: an in vitro study
ATE245448T1 (de) Zellwachstumshemmende zusammensetzungen die kalzium-zufluss-blocker enthalten

Legal Events

Date Code Title Description
ST Notification of lapse